MaxCyte
MXCT
104 hedge funds and large institutions have $376M invested in MaxCyte in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 46 increasing their positions, 29 reducing their positions, and 11 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.87% less ownership
Funds ownership: 68.41% → 67.54% (-0.87%)
10% less call options, than puts
Call options by funds: $19K | Put options by funds: $21K
4% less funds holding
Funds holding: 108 → 104 (-4)
17% less capital invested
Capital invested by funds: $452M → $376M (-$76.3M)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.93M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.54M |
| 3 |
Millennium Management
New York
|
+$2.91M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.37M |
| 5 |
BlackRock
New York
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$7.55M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$3.52M |
| 3 |
Citigroup
New York
|
-$3.12M |
| 4 |
Goldman Sachs
New York
|
-$2.06M |
| 5 |
Holocene Advisors
New York
|
-$1.87M |
MXCT Hedge Fund Activity: Q4 2022 in Review
104 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q4 2022, worth a combined $376M — down 17% from $452M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MXCT and 7 opened new positions — a net loss of 4 holders — while 29 trimmed existing stakes and 46 added.
The largest buyer was Citadel Advisors, adding an estimated $5.93M. The largest seller was Casdin Capital, cutting an estimated $7.55M.
- 104 institutional investors held MaxCyte (MXCT) as of Q4 2022, down from 108 in Q3 2022.
- Funds reported $376M of MaxCyte stock for Q4 2022, down 17% quarter-over-quarter.
- 7 funds opened new MaxCyte positions in Q4 2022 and 11 closed out, a net change of -4 holders.
- The largest MaxCyte buyer in Q4 2022 was Citadel Advisors, an estimated $5.93M added.
- The largest MaxCyte seller in Q4 2022 was Casdin Capital, an estimated $7.55M sold.
Based on aggregated 13F filings for Q4 2022.